Gufic Biosciences Ltd
GUFICBIO
Company Profile
Business description
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
Contact
SM House, 11 Sahakar Road
1st to 4th Floor
Vile Parle (East)
MumbaiMH400 057
INDT: +91 2267261000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,926
Stocks News & Analysis
stocks
ASX healthcare giant remains well positioned despite share slump
We welcome the CEO change at CSL but relatively soft plasma performance will postpone recovery
stocks
Australian bank remains overvalued despite strong result
When strong fundamentals meet persistent valuation headwinds.
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
The latest take from our equity research analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 41.30 | -0.44% |
| CAC 40 | 8,313.24 | 14.64 | -0.18% |
| DAX 40 | 24,856.15 | 131.70 | -0.53% |
| Dow JONES (US) | 50,121.40 | 66.74 | -0.13% |
| FTSE 100 | 10,472.11 | 118.27 | 1.14% |
| HKSE | 27,070.18 | 196.20 | -0.72% |
| NASDAQ | 23,066.47 | 36.01 | -0.16% |
| Nikkei 225 | 57,695.67 | 45.13 | 0.08% |
| NZX 50 Index | 13,531.48 | 24.20 | 0.18% |
| S&P 500 | 6,941.47 | 0.34 | -0.00% |
| S&P/ASX 200 | 9,043.50 | 18.50 | -0.20% |
| SSE Composite Index | 4,136.59 | 4.61 | 0.11% |